Evidence map›Paper›PMID 35850199›Full record

ArticleGastroenterology2022

A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines.

Taisuke Baba, Pascal Finetti, Pancreatic Cancer Group, Keith D Lillemoe, Andrew L Warshaw, Carlos Fernández-Del Castillo, Andrew S Liss

Abstract read
In one paragraph

Article in Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Article
  4. Article
  5. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Taisuke BabaDepartment of Surgery, Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts.
Pascal FinettiDepartment of Predictive Oncology, Cancer Research Center of Marseille, U1068 INSERM, UMR 7258 CNRS, Institut Paoli Calmettes, Aix-Marseille University, Marseille, France.
Pancreatic Cancer Group
Keith D LillemoeDepartment of Surgery, Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts.
Andrew L WarshawDepartment of Surgery, Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts.
Carlos Fernández-Del CastilloDepartment of Surgery, Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts.
Andrew S LissDepartment of Surgery, Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts. Electronic address: aliss@mgh.harvard.edu.

Funding

Epigenetic Regulation of Hemidesmosome Signaling in Pancreatic CancerR03CA241971 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LISS, ANDREW · 2020 to 2020
$166k
NCI NIH HHS R03 CA241971
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsCell LineHumansPancreatic Ducts

Identifiers

PMID35850199
PMCPMC9613505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.